

Surgery Phase 2, 2014 Standing Committee: In-Person Meeting Summary

March 19-20, 2015

The Surgery Standing Committee met in-person on March, 19-20, 2015, at the NQF offices in Washington, D.C. to evaluate 24 measures. Additionally, they provided feedback and guidance on the role of the standing committee in overseeing the NQF Surgery portfolio of measures.

- **Welcome, Introductions, and Disclosures of Interest**
 - The Committee co-chairs and NQF staff introduced the NQF Surgery project team and welcomed the Committee to the second phase of the Surgery Endorsement project.
 - NQF's Senior Vice President of Quality Measurement presented NQF's Conflict of Interest Policy. Each Committee member introduced themselves and disclosed any potential conflicts of interest.
- **Project Introduction and Overview of Evaluation Process**
 - Staff reviewed:
 - The role of the Standing Committee, ground rules for Committee member discussion and the NQF measure endorsement criteria,
 - The current Surgery portfolio of measures, noting that it is one of NQF's largest portfolios of measures, and gave a brief tutorial of the voting software.
 - The co-chairs facilitated a discussion related to 30-day mortality measures in terms of potential unintended consequences.
- **Measure Evaluation**
 - **0354: Hip Fracture Mortality Rate (IQI 9) (AHRQ)**
 - Developer Representatives: Patrick Romano, Carol Stocks, Garth Utter, and Sheryl Davies
 - Votes
 - Evidence – 22-Y; 0-N
 - Opportunity for Improvement – 16-H; 4-M; 1-L; 0-I
 - Reliability – 9-H; 13-M; 1-L; 0-I
 - Validity – 2-H; 15-M; 5-L; 0-I
 - Feasibility – 17-H; 6-M; 0-L; 0-I
 - Usability and Use – 5-H; 16-M; 1-L; 0-I
 - Overall Recommendation – 20-Y; 2-N
 - The Committee recommended this measure for continued endorsement. A summary of the Committee deliberations will be compiled and provided in the draft report.
 - **0360: Esophageal Resection Mortality Rate (IQI 8) (AHRQ)**
 - Developer Representatives: Patrick Romano, Carol Stocks, Garth Utter, and Sheryl Davies
 - Votes
 - Evidence – 22-Y; 1-N
 - Opportunity for Improvement – 9-H; 14-M; 0-L; 0-I
 - Reliability – 0-H; 4-M; 16-L; 3-I
 - Validity – no votes collected
 - Feasibility – no votes collected

- Usability and Use – no votes collected
 - Overall Recommendation – no votes collected
- The Committee did not recommend this measure for continued endorsement. A summary of the Committee deliberations will be compiled and provided in the draft report.
- **0361: Esophageal Resection Volume (IQI 1) (AHRQ)**
 - Developer Representatives: Patrick Romano, Carol Stocks, Garth Utter, and Sheryl Davies
 - Votes
 - Evidence – no votes collected
 - Opportunity for Improvement – no votes collected
 - Reliability – no votes collected
 - Validity – no votes collected
 - Feasibility – no votes collected
 - Usability and Use – no votes collected
 - Overall Recommendation – no votes collected
 - The Committee recommended this measure be held from voting. The developer may submit a new measure in the form of a composite that encompasses measures 0360 and 0361. If the developer is able to submit the new composite measure in a timely manner, the Committee would be willing to review it as part of this current project.
- **0533: Postoperative Respiratory Failure Rate (IQI 11) (AHRQ)**
 - Developer Representatives: Patrick Romano, Carol Stocks, Garth Utter, and Sheryl Davies
 - Votes
 - Evidence – 22-Y; 1-N
 - Opportunity for Improvement – 16-H; 6-M; 0-L; 0-I
 - Reliability – 7-H; 15-M; 1-L; 0-I
 - Validity – 1-H; 13-M; 8-L; 0-I
 - Feasibility – 13-H; 9-M; 0-L; 0-I
 - Usability and Use – 8-H; 10-M; 5-L; 0-I
 - Overall Recommendation – 21-Y; 2-N
 - The Committee recommended this measure for continued endorsement. A summary of the Committee deliberations will be compiled and provided in the draft report.
- **0236: CABG: Perioperative Beta-blocker in Patients with Isolated CABG Surgery (CMS)**
 - Developer Representatives: Jane Lucas, Sven Berg, Hiral Dudhwala, and Gary Rezek
 - Votes
 - Evidence – 6-H; 12-M; 3-L; 1-I
 - Opportunity for Improvement – 5-H; 10-M; 7-L; 0-I
 - Reliability – 5-H; 15-M; 1-L; 0-I
 - Validity – 2-H; 14-M; 6-L; 0-I
 - Feasibility – 2-H; 16-M; 4-L; 0-I
 - Usability and Use – 2-H; 16-M; 4-L; 0-I
 - Overall Recommendation – 17-Y; 5-N

- The Committee recommended this measure for continued endorsement. A summary of the Committee deliberations will be compiled and provided in the draft report.
- **0465: Perioperative Anti-platelet Therapy for Patients Undergoing Carotid Endarterectomy (SVS)**
 - Developer Representatives: Jill Rathbun, Brad Johnson, Vivienne Halpern, and Rocco Ciocca
 - Votes
 - Evidence – 1-H; 17-M; 3-L; 0-I
 - Opportunity for Improvement – 9-H; 14-M; 1-L; 0-I
 - Reliability – 19-H; 4-M; 0-L; 0-I
 - Validity – 13-H; 9-M; 0-L; 0-I
 - Feasibility – 8-H; 13-M; 2-L; 1-I
 - Usability and Use – 7-H; 15-M; 2-L; 0-I
 - Overall Recommendation – 23-Y; 1-N
 - The Committee recommended this measure for continued endorsement. A summary of the Committee deliberations will be compiled and provided in the draft report.
- **2038: Performing Vaginal Apical Suspension at the time of Hysterectomy to Address Pelvic Organ Prolapse (AUGS)**
 - Developer Representatives: Samantha Pulliam, Daniel Morgan, Colleen Hughes, Jill Rathbun, Rony Adam, and Mark Preston
 - Votes
 - Evidence – 5-H; 17-M; 1-L; 0-I
 - Opportunity for Improvement – 19-H; 4-M; 0-L; 0-I
 - Reliability – 8-H; 13-M; 4-L; 0-I
 - Validity – 2-H; 16-M; 6-L; 0-I
 - Feasibility – 0-H; 16-M; 8-L; 0-I
 - Usability and Use – 3-H; 17-M; 4-L; 0-I
 - Overall Recommendation – 22-Y; 2-N
 - The Committee recommended this measure for endorsement. A summary of the Committee deliberations will be compiled and provided in the draft report.
- **2677: Preoperative Evaluation for Stress Urinary Incontinence prior to Hysterectomy for Pelvic Organ Prolapse (AUGS)**
 - Developer Representatives: Samantha Pulliam, Daniel Morgan, Colleen Hughes, Jill Rathbun, Rony Adam, and Mark Preston
 - Votes
 - Evidence – 0-H; 14-M; 5-L; 2-I
 - Opportunity for Improvement – 5-H; 15-M; 2-L; 0-I
 - Reliability – 2-H; 19-M; 2-L; 0-I
 - Validity – 1-H; 20-M; 2-L; 0-I
 - Feasibility – 1-H; 15-M; 5-L; 1-I
 - Usability and Use – 1-H; 14-M; 7-L; 0-I
 - Overall Recommendation – 16-Y; 6-N

- The Committee recommended this measure for endorsement. A summary of the Committee deliberations will be compiled and provided in the draft report.
- **2681: Perioperative Temperature Management (ASA)**
 - Developer Representatives: Thomas Miller, Matthew Popovich, and James Moore
 - Votes
 - Evidence – 13-H; 7-M; 0-L; 0-I; 1-IE
 - Opportunity for Improvement – 2-H; 18-M; 0-L; 0-I
 - Reliability – 4-H; 13-M; 3-L; 0-I
 - Validity – 3-H; 13-M; 4-L; 0-I
 - Feasibility – 11-H; 7-M; 1-L; 0-I
 - Usability and Use – 10-H; 8-M; 1-L; 0-I
 - Overall Recommendation – 19-Y; 0-N
 - The Committee recommended this measure for endorsement. A summary of the Committee deliberations will be compiled and provided in the draft report.
- **2687: Hospital Visits after Hospital Outpatient Surgery (Yale-CORE)**
 - Developer Representatives: Elizabeth Drye and Craig Parzynski
 - Votes
 - Evidence – 15-Y; 3-N
 - Opportunity for Improvement – 5-H; 13-M; 2-L; 0-I
 - Reliability – 2-H; 15-M; 0-L; 0-I
 - Validity – 3-H; 16-M; 0-L; 0-I
 - Feasibility – 16-H; 3-M; 0-L; 0-I
 - Usability and Use – 6-H; 11-M; 1-L; 0-I
 - Overall Recommendation – 18-Y; 1-N
 - The Committee recommended this measure for endorsement. A summary of the Committee deliberations will be compiled and provided in the draft report.
- **0732: Surgical Volume for Pediatric and Congenital Heart Surgery: Total Programmatic Volume and Programmatic Volume Stratified by the 5 STAT Mortality Categories (STS)**
 - Developer Representatives: Jeffrey Jacobs, David Shahian, Max He, Jane Ha, and Jamie Yap
 - Votes
 - Evidence – 9-H; 7-M; 4-L; 0-I
 - Opportunity for Improvement – 10-H; 8-M; 2-L; 0-I
 - Reliability – 15-H; 4-M; 0-L; 0-I
 - Validity – 12-H; 16-M; 2-L; 0-I
 - Feasibility – 15-H; 6-M; 0-L; 0-I
 - Usability and Use – 17-H; 2-M; 1-L; 0-I
 - Overall Recommendation – 18-Y; 2-N
 - The Committee recommended this measure for continued endorsement. A summary of the Committee deliberations will be compiled and provided in the draft report.
- **0733: Operative Mortality Stratified by the Five STAT Mortality Categories (STS)**
 - Developer Representatives: Jeffrey Jacobs, David Shahian, Max He, Jane Ha, and Jamie Yap

- Votes
 - Evidence – 21-Y; 0-N
 - Opportunity for Improvement – 8-H; 10-M; 1-L; 0-I
 - Reliability – 16-H; 4-M; 1-L; 0-I
 - Validity – 17-H; 3-M; 1-L; 0-I
 - Feasibility – 15-H; 4-M; 1-L; 0-I
 - Usability and Use – 14-H; 5-M; 1-L; 0-I
 - Overall Recommendation – 21-Y; 0-N
- The Committee recommended this measure for continued endorsement. A summary of the Committee deliberations will be compiled and provided in the draft report.
- **2683: Risk-Adjusted Operative Mortality for Pediatric and Congenital Heart Surgery (STS)**
 - Developer Representatives: Jeffrey Jacobs, David Shahian, Max He, Jane Ha, and Jamie Yap
 - Votes
 - Evidence – 21-Y; 0-N
 - Opportunity for Improvement – 12-H; 9-M; 0-L; 0-I
 - Reliability – 18-H; 3-M; 0-L; 0-I
 - Validity – 13-H; 8-M; 0-L; 0-I
 - Feasibility – 15-H; 4-M; 1-L; 0-I
 - Usability and Use – 14-H; 5-M; 1-L; 0-I
 - Overall Recommendation – 20-Y; 0-N
 - The Committee recommended this measure for endorsement. A summary of the Committee deliberations will be compiled and provided in the draft report.
- **0115: Risk-Adjusted Surgical Re-exploration (STS)**
 - Developer Representatives: Jeffrey Jacobs, David Shahian, Max He, Jane Ha, and Jamie Yap
 - Votes
 - Evidence – 19-Y; 1-N
 - Opportunity for Improvement – 12-H; 9-M; 0-L; 0-I
 - Reliability – 15-H; 6-M; 0-L; 0-I
 - Validity – 16-H; 4-M; 0-L; 0-I
 - Feasibility – 15-H; 6-M; 1-L; 0-I
 - Usability and Use – 18-H; 4-M; 0-L; 0-I
 - Overall Recommendation – 22-Y; 0-N
 - The Committee recommended this measure for continued endorsement. A summary of the Committee deliberations will be compiled and provided in the draft report.
- **0130: Risk-Adjusted Deep Sternal Wound Infection Rate (STS)**
 - Developer Representatives: Jeffrey Jacobs, David Shahian, Max He, Jane Ha, and Jamie Yap
 - Votes
 - Evidence – 21-Y; 0-N
 - Opportunity for Improvement – 8-H; 12-M; 1-L; 0-I
 - Reliability – 15-H; 6-M; 0-L; 0-I
 - Validity – 14-H; 7-M; 0-L; 0-I

- Feasibility – 15-H; 6-M; 1-L; 0-I
 - Usability and Use – 18-H; 4-M; 0-L; 0-I
 - Overall Recommendation – 22-Y; 0-N
 - The Committee recommended this measure for continued endorsement. A summary of the Committee deliberations will be compiled and provided in the draft report.
- **0116: Anti-platelet Medication at Discharge (STS)**
- Developer Representatives: Jeffrey Jacobs, David Shahian, Max He, Jane Ha, and Jamie Yap
 - Votes
 - Evidence – 14-H; 7-M; 0-L; 0-I
 - Opportunity for Improvement – 1-H; 3-M; 17-L; 1-I
 - Reliability – 15-H; 6-M; 0-L; 0-I
 - Validity – 12-H; 7-M; 1-L; 0-I
 - Feasibility – 15-H; 6-M; 1-L; 0-I
 - Usability and Use – 18-H; 4-M; 0-L; 0-I
 - Overall Recommendation – 20-Y; 0-N
 - The Committee recommended this measure for continued endorsement in reserve status. A summary of the Committee deliberations will be compiled and provided in the draft report.
- **0118: Anti-lipid Treatment at Discharge (STS)**
- Developer Representatives: Jeffrey Jacobs, David Shahian, Max He, Jane Ha, and Jamie Yap
 - Votes
 - Evidence – 6-H; 9-M; 3-L; 0-I; 1-IE
 - Opportunity for Improvement – 2-H; 15-M; 4-L; 0-I
 - Reliability – 15-H; 6-M; 0-L; 0-I
 - Validity – 13-H; 9-M; 0-L; 0-I
 - Feasibility – 15-H; 6-M; 1-L; 0-I
 - Usability and Use – 18-H; 4-M; 0-L; 0-I
 - Overall Recommendation – 21-Y; 1-N
 - The Committee recommended this measure for continued endorsement. A summary of the Committee deliberations will be compiled and provided in the draft report.
- **0120: Risk-Adjusted Operative Mortality for Aortic Valve Replacement (AVR) (STS)**
- Developer Representatives: Jeffrey Jacobs, David Shahian, Max He, Jane Ha, and Jamie Yap
 - Votes
 - Evidence – 19-Y; 1-N
 - Opportunity for Improvement – 8-H; 14-M; 0-L; 0-I
 - Reliability – 15-H; 6-M; 0-L; 0-I
 - Validity – 16-H; 5-M; 0-L; 0-I
 - Feasibility – 15-H; 6-M; 1-L; 0-I
 - Usability and Use – 18-H; 4-M; 0-L; 0-I
 - Overall Recommendation – 21-Y; 1-N

- The Committee recommended this measure for continued endorsement. A summary of the Committee deliberations will be compiled and provided in the draft report.
- **0123: Risk-Adjusted Operative Mortality for AVR + CABG Surgery (STS)**
 - Developer Representatives: Jeffrey Jacobs, David Shahian, Max He, Jane Ha, and Jamie Yap
 - Votes
 - Evidence – 20-Y; 1-N
 - Opportunity for Improvement – 10-H; 10-M; 1-L; 0-I
 - Reliability – 15-H; 6-M; 0-L; 0-I
 - Validity – 18-H; 4-M; 0-L; 0-I
 - Feasibility – 15-H; 6-M; 1-L; 0-I
 - Usability and Use – 18-H; 4-M; 0-L; 0-I
 - Overall Recommendation – 22-Y; 0-N
 - The Committee recommended this measure for continued endorsement. A summary of the Committee deliberations will be compiled and provided in the draft report.
- **0121: Risk-Adjusted Operative Mortality for Mitral Valve (MV) (STS)**
 - Developer Representatives: Jeffrey Jacobs, David Shahian, Max He, Jane Ha, and Jamie Yap
 - Votes
 - Evidence – 20-Y; 0-N
 - Opportunity for Improvement – 10-H; 11-M; 0-L; 1-O
 - Reliability – 15-H; 6-M; 0-L; 0-I
 - Validity – 13-H; 7-M; 0-L; 1-O
 - Feasibility – 15-H; 6-M; 1-L; 0-I
 - Usability and Use – 18-H; 4-M; 0-L; 0-I
 - Overall Recommendation – 22-Y; 0-N
 - The Committee recommended this measure for continued endorsement. A summary of the Committee deliberations will be compiled and provided in the draft report.
- **0122: Risk-Adjusted Operative Mortality MV Replacement + CABG Surgery (STS)**
 - Developer Representatives: Jeffrey Jacobs, David Shahian, Max He, Jane Ha, and Jamie Yap
 - Votes
 - Evidence – 19-Y; 1-N
 - Opportunity for Improvement – 9-H; 12-M; 0-L; 0-I
 - Reliability – 15-H; 6-M; 0-L; 0-I
 - Validity – 12-H; 7-M; 0-L; 0-I
 - Feasibility – 15-H; 6-M; 1-L; 0-I
 - Usability and Use – 18-H; 4-M; 0-L; 0-I
 - Overall Recommendation – 19-Y; 0-N
 - The Committee recommended this measure for continued endorsement. A summary of the Committee deliberations will be compiled and provided in the draft report.
- **1501: Risk-Adjusted Operative Mortality for MV Repair (STS)**
 - Developer Representatives: Jeffrey Jacobs, David Shahian, Max He, Jane Ha, and Jamie Yap
 - Votes

- Evidence – 21-Y; 0-N
 - Opportunity for Improvement – 6-H; 15-M; 0-L; 0-I
 - Reliability – 15-H; 6-M; 0-L; 0-I
 - Validity – 16-H; 6-M; 0-L; 0-I
 - Feasibility – 15-H; 6-M; 1-L; 0-I
 - Usability and Use – 18-H; 4-M; 0-L; 0-I
 - Overall Recommendation – 20-Y; 0-N
- The Committee recommended this measure for continued endorsement. A summary of the Committee deliberations will be compiled and provided in the draft report.
- **1502: Risk-Adjusted Operative Mortality for MV Repair + CABG Surgery (STS)**
 - Developer Representatives: Jeffrey Jacobs, David Shahian, Max He, Jane Ha, and Jamie Yap
 - Votes
 - Evidence – 19-Y; 0-N
 - Opportunity for Improvement – 9-H; 10-M; 0-L; 0-I
 - Reliability – 15-H; 6-M; 0-L; 0-I
 - Validity – 11-H; 8-M; 0-L; 0-L
 - Feasibility – 15-H; 6-M; 1-L; 0-I
 - Usability and Use – 18-H; 4-M; 0-L; 0-I
 - Overall Recommendation – 19-Y; 0-N
 - The Committee recommended this measure for continued endorsement. A summary of the Committee deliberations will be compiled and provided in the draft report.
- **0696: The STS CABG Composite Score (STS)**
 - Developer Representatives: Jeffrey Jacobs, David Shahian, Max He, Jane Ha, and Jamie Yap
 - Votes
 - Evidence – 18-Y; 1-N
 - Opportunity for Improvement – 10-H; 8-M; 0-L; 0-I
 - Composite – 16-H; 3-M; 0-I; 0-I
 - Reliability – 14-H; 5-M; 0-L; 0-I
 - Validity – 12-H; 7-M; 0-I; 0-I
 - Feasibility – 15-H; 4-M; 0-L; 0-I
 - Usability and Use – 15-H; 4-L; 0-L; 0-I
 - Overall Recommendation – 18-Y; 0-N
 - The Committee recommended this measure for continued endorsement. A summary of the Committee deliberations will be compiled and provided in the draft report.
- **Harmonization**
 - Prior to the meeting, NQF staff identified potential areas for harmonization and communicated this to the measure developers. At the in-person meeting, the Committee discussed potential related and competing measures and suggested next steps for the developers. NQF will provide these details along with the harmonization decisions in the Phase 2 Draft Report.

- **Gaps in Portfolio of Surgery–related measures**
 - Because of the robust discussion during the measure evaluation portion of the meeting, the Committee agreed to postpone the discussion regarding gaps in the surgery portfolio. NQF Staff has solicited feedback from the Committee via email and the results of their input and subsequent discussion will be incorporated into the Phase 2 Draft Report for Surgery Measure Endorsement.
- **Next Steps in Project and Committee Timeline**
 - NQF Staff will synthesize committee discussion and submit the draft report for member and public commenting from April 17 – May 18, 2015.
 - Member Voting will be held from June 19 – July 6. The Surgery Standing Committee will have a call to review and respond to comments on June 8, 2015.
 - The measures will go to the Consensus Standards Approval Committee (CSAC) for discussion from July 7 – July 27, 2015.
 - The NQF Board will have the final report and vote for review from July 28 –August 6, 2015 and the report will go through Appeals from August 7 – September 8, 2015.